| Objective To explore the effect of joint physician-pharmacist assessment of medication risk on improving the safety of peri-pregnancy women's medication use. Methods The cases of medication consultation for 107 peri-pregnant women in prenatal consultation outpatient of Binhu Hospital from August 2021 to November 2021 were selected. The drug exposure registration and pregnancy outcome follow-up table were established, and the basic information of patients, medication information, pregnancy outcome and neonatal outcome were collected and retrospectively analyzed. Emphasis was placed on tracking pregnancy and newborn outcomes of patients using medications without safety data, and pregnancy and newborn outcomes in patients vaccinated with different types of novel coronavirus vaccine (referred to as COVID-19 vaccine) weer compared. Results The average age of patients in the 107 peri-pregnancy women’s medication counseling was 30.58±5.12 years old, the number of medications per capita was 2.71±2.05, and the top three categories of medications used were, in terms of frequency, biological products (33.89%), traditional Chinese medicines (23.89%), and anti-infective medications (15.56%). From the date of consultation to the pregnancy termination, the average number of tracking days was (126.21±57.77) days, and 71 (66.36%) pregnancy outcomes were tracked, 5 cases (4.67%) voluntarily chose artificial termination of pregnancy, including 1 case (0.93%) with abnormal fetal structural abnormalities. Forty-five(42.06%) patients who were focused on tracking perinatal medication had favorable pregnancy outcomes and there was no malformation of newborns. There was no significant difference in delivery mode, delivery number, gestational age, sex, length, weight, the neonatal pathological condition and Apgar score between the patients vaccinated with two different types of COVID-19 vaccines (inactivated vaccine and protein subunit vaccine) (P>0.05). Conclusions By conducting the joint physician-pharmacist assessment of medication risk, scientific and personalized medication suggestions and clinical guidance can be provided for patients, which facilitates the registration and collection of evidence-based medical evidence for perinatal medication, and promotes the establishment of the perinatal medication risk classification system in China. |
